ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites
Alejandra Martínez-Chávez, Nancy H.C. Loos, Maria C. Lebre, Matthijs M. Tibben, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel
Topics & Concepts
PharmacologyPharmacokineticsAbcg2CmaxCYP3A4CYP3AChemistryFexofenadineBiologyMedicineInternal medicineTransporterMetabolismBiochemistryATP-binding cassette transporterCytochrome P450GeneAdvanced Breast Cancer TherapiesChronic Lymphocytic Leukemia ResearchNeuroendocrine Tumor Research Advances